Anixa Biosciences Inc (ANIX) News & EventsANIXAnixa Biosciences Inc

Anixa Biosciences Completes Dosing of Fifth Cohort in Clinical Trial

Anixa Biosciences has completed dosing of the fifth cohort in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The sixth cohort is expected to commence following a routine 30-day safety verification. The Phase 1 study is evaluating a novel CAR-T therapy targeting follicle stimulating hormone receptor, which is expressed on ovarian cancer cells but has limited expression in healthy tissues. The trial is designed to assess safety, tolerability, and preliminary signs of efficacy across escalating dose levels. To date, no dose-limiting toxicities have been observed across any cohort. As of this date, four patients in the study have surpassed one year of survival following treatment, with individual patients surviving approximately 28, 21, 17, and 17 months post-treatment, respectively. In addition, the first patient treated in the fifth dose cohort exhibited stable disease 90 days after treatment. The company believes these outcomes are notable in a highly pre-treated, recurrent ovarian cancer population that has progressed after multiple prior lines of therapy and limited treatment options and poor prognosis. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute.

Anixa Biosciences CAR-T Therapy Shows First Patient Stable Disease

Anixa Biosciences announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment. This represents the first such response in Anixa's CAR-T cell therapy trial. Correlative studies evaluating presence and durability of CAR positive cells are ongoing. The patient was treated in the fifth dose cohort and received a dose of 110 CAR-positive cells per kilogram of body weight following lymphodepletion, representing the highest dose level evaluated to date in the study. To date, no dose-limiting toxicities have been observed in any patients.

Anixa Biosciences Treats Second Patient in Clinical Trial

Anixa Biosciences announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The study is being conducted at Moffitt Cancer Center.